Fredun Pharmaceuticals Limited (BOM:539730)
India · Delayed Price · Currency is INR 906.70
+11.50 (1.28%)
At close: Jul 27, 2026
Fredun Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 14,995 | 8,072 | 3,142 | 3,371 | 3,572 | 4,057 | |
Market Cap Growth | 244.47% | 156.94% | -6.80% | -5.63% | -11.97% | 119.38% |
Enterprise Value | 16,767 | 9,695 | 4,496 | 3,993 | 4,419 | 4,511 |
Last Close Price | 906.70 | 557.12 | 222.66 | 238.68 | 258.42 | 304.12 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 44.43 | 24.75 | 15.92 | 21.58 | 33.05 | 64.04 |
PS Ratio | 2.36 | 1.27 | 0.69 | 0.97 | 1.30 | 1.81 |
PB Ratio | 5.39 | 2.90 | 2.22 | 2.78 | 3.71 | 5.96 |
P/TBV Ratio | 5.40 | 2.91 | 2.23 | 2.79 | 3.72 | 5.97 |
P/OCF Ratio | 125.99 | 67.82 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 2.64 | 1.53 | 0.99 | 1.15 | 1.61 | 2.01 |
EV/EBITDA Ratio | 18.46 | 10.68 | 8.40 | 10.50 | 15.82 | 32.51 |
EV/EBIT Ratio | 20.29 | 11.73 | 9.25 | 11.64 | 17.56 | 38.42 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.87 | 0.87 | 1.19 | 0.87 | 0.90 | 0.89 |
Debt / EBITDA Ratio | 2.67 | 2.67 | 3.15 | 2.77 | 3.10 | 4.37 |
Net Debt / Equity Ratio | 0.64 | 0.64 | 1.15 | 0.85 | 0.86 | 0.86 |
Net Debt / EBITDA Ratio | 1.95 | 1.95 | 3.05 | 2.72 | 2.98 | 4.22 |
Net Debt / FCF Ratio | -2.87 | -2.87 | -7.19 | -12.80 | -3.48 | -8.78 |
Asset Turnover | 1.13 | 1.13 | 1.14 | 1.23 | 1.24 | 1.29 |
Inventory Turnover | 1.85 | 1.85 | 1.69 | 1.70 | 2.23 | 3.23 |
Quick Ratio | 0.53 | 0.53 | 0.56 | 0.40 | 0.27 | 1.25 |
Current Ratio | 1.68 | 1.68 | 1.30 | 1.54 | 1.55 | 2.07 |
Return on Equity (ROE) | 15.55% | 15.55% | 15.02% | 14.34% | 13.14% | 11.40% |
Return on Assets (ROA) | 9.14% | 9.14% | 7.65% | 7.59% | 7.08% | 4.21% |
Return on Invested Capital (ROIC) | 14.80% | 15.10% | 13.19% | 12.35% | 10.15% | 8.07% |
Return on Capital Employed (ROCE) | 23.90% | 23.90% | 30.50% | 24.40% | 21.40% | 10.40% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 2.18% | 4.04% | 6.28% | 4.63% | 3.03% | 1.56% |
FCF Yield | -4.11% | -7.64% | -7.23% | -2.40% | -6.69% | -1.64% |
Dividend Yield | 0.03% | 0.04% | 0.10% | 0.10% | 0.09% | 0.08% |
Buyback Yield / Dilution | -14.78% | -14.78% | - | -3.66% | -7.85% | -4.06% |
Total Shareholder Return | -14.75% | -14.74% | 0.10% | -3.56% | -7.76% | -3.98% |